Literature DB >> 15683221

Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics.

Neil H Segal1, Nathalie E Blachere, Jose A Guevara-Patiño, Humilidad F Gallardo, Ho Yin A Shiu, Agnes Viale, Cristina R Antonescu, Jedd D Wolchok, Alan N Houghton.   

Abstract

Cancer-testis or germ cell antigens (GCAs) are a category of tumor antigens expressed by male germ cells and by cancers of diverse histological origin, but not usually by normal adult somatic tissue. These antigens include products encoded by the MAGE, BAGE, GAGE, SSX, and LAGE/NY-ESO-1 families that encode antigenic peptides recognized by T lymphocytes. In this study, we exploit oligonucleotide technology to identify genes in melanoma and soft tissue sarcoma (STS) that display a cancer-testis/GCA expression profile. We identified 59 such genes, including GCAs we knew to be recognized by T lymphocytes. Among our findings are the expression of PRAME in monophasic synovial sarcoma, PRAME and NY-ESO-1 in myxoid/round cell liposarcoma, and SSX2 and members of the GAGE family in malignant fibrous histiocytoma. Furthermore, the proto-oncogene DBL/MCF2 was identified as encoding a novel candidate GCA expressed by clear cell sarcoma/melanoma of soft parts (MSP). DBL/MCF2 peptides that are bound to HLA-A*0201 were identified and recognized by T lymphocytes. These results show the utility of high-throughput expression analysis in the efficient screening and identification of GCA candidates in cancer, and its application to the discovery of candidate targets for T cell immunity against GCAs expressed by cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15683221

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  16 in total

1.  Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Authors:  Rachel E Beard; Daniel Abate-Daga; Shannon F Rosati; Zhili Zheng; John R Wunderlich; Steven A Rosenberg; Richard A Morgan
Journal:  Clin Cancer Res       Date:  2013-09-10       Impact factor: 12.531

2.  PRAME expression in hairy cell leukemia.

Authors:  Evgeny Arons; Tara Suntum; Inger Margulies; Constance Yuan; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Leuk Res       Date:  2008-03-04       Impact factor: 3.156

Review 3.  Cryoimmunology for malignant bone and soft-tissue tumors.

Authors:  Hideji Nishida; Norio Yamamoto; Yoshikazu Tanzawa; Hiroyuki Tsuchiya
Journal:  Int J Clin Oncol       Date:  2011-03-12       Impact factor: 3.402

4.  Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.

Authors:  Jessica A Hemminger; Amanda Ewart Toland; Thomas J Scharschmidt; Joel L Mayerson; Denis C Guttridge; O Hans Iwenofu
Journal:  Mod Pathol       Date:  2014-01-24       Impact factor: 7.842

5.  NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.

Authors:  Seth M Pollack; Achim A Jungbluth; Benjamin L Hoch; Erik A Farrar; Marie Bleakley; David J Schneider; Elizabeth T Loggers; Eve Rodler; Janet F Eary; Ernest U Conrad; Robin L Jones; Cassian Yee
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

6.  Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

Authors:  Katayoun Rezvani; Agnes S M Yong; Abdul Tawab; Behnam Jafarpour; Rhoda Eniafe; Stephan Mielke; Bipin N Savani; Keyvan Keyvanfar; Yixin Li; Roger Kurlander; A John Barrett
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

7.  Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.

Authors:  Maud Condomines; Dirk Hose; Thierry Rème; Guilhem Requirand; Michael Hundemer; Matthieu Schoenhals; Hartmut Goldschmidt; Bernard Klein
Journal:  J Immunol       Date:  2009-06-19       Impact factor: 5.422

Review 8.  Targeting cancer testis antigens in synovial sarcoma.

Authors:  Geoffrey Mitchell; Seth M Pollack; Michael J Wagner
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

9.  Immunotherapy targets in pediatric cancer.

Authors:  Rimas J Orentas; Daniel W Lee; Crystal Mackall
Journal:  Front Oncol       Date:  2012-01-30       Impact factor: 6.244

10.  A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

Authors:  Robert G Maki; Achim A Jungbluth; Sacha Gnjatic; Gary K Schwartz; David R D'Adamo; Mary Louise Keohan; Michael J Wagner; Kelly Scheu; Rita Chiu; Erika Ritter; Jennifer Kachel; Israel Lowy; Lloyd J Old; Gerd Ritter
Journal:  Sarcoma       Date:  2013-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.